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Abstract
Introduction: The majority of postmenopausal breast cancers are estrogen-dependent. Tumor-derived factors, such
as prostaglandin E2 (PGE2), stimulate CREB1 binding to cAMP response elements (CREs) on aromatase promoter II
(PII), leading to the increased expression of aromatase and biosynthesis of estrogens within human breast adipose
stromal cells (ASCs). Hypoxia inducible factor-1a (HIF-1a), a key mediator of cellular adaptation to low oxygen
levels, is emerging as a novel prognostic marker in breast cancer. We have identified the presence of a consensus
HIF-1a binding motif overlapping with the proximal CRE of aromatase PII. However, the regulation of aromatase
expression by HIF-1a in breast cancer has not been characterized. This study aimed to characterize the role of
HIF-1a in the activation of aromatase PII.
Methods: HIF-1a expression and localization were examined in human breast ASCs using quantitative PCR (QPCR),
Western blotting, immunofluorescence and high content screening. QPCR and tritiated water-release assays were
performed to assess the effect of HIF-1a on aromatase expression and activity. Reporter assays and chromatin
immunoprecipitation (ChIP) were performed to assess the effect of HIF-1a on PII activity and binding. Treatments
included PGE2 or DMOG ((dimethyloxalglycine), HIF-1a stabilizer). Double immunohistochemistry for HIF-1a and
aromatase was performed on tissues obtained from breast cancer and cancer-free patients.
Results: Results indicate that PGE2 increases HIF-1a transcript and protein expression, nuclear localization and
binding to aromatase PII in human breast ASCs. Results also demonstrate that HIF-1a significantly increases PII
activity, and aromatase transcript expression and activity, in the presence of DMOG and/or PGE2, and that HIF-1a
and CREB1 act co-operatively on PII. There is a significant increase in HIF-1a positive ASCs in breast cancer patients
compared to cancer-free women, and a positive association between HIF-1a and aromatase expression.
Conclusions: This study is the first to identify HIF-1a as a modulator of PII-driven aromatase expression in human
breast tumor-associated stroma and provides a novel mechanism for estrogen regulation in obesity-related, post-
menopausal breast cancer. Together with our on-going studies on the role of AMP-activated protein kinase (AMPK) in
the regulation of breast aromatase, this work provides another link between disregulated metabolism and breast
cancer.
Introduction
Epidemiological studies indicate that the proportion of
estrogen-dependent breast cancer cases is dramatically
increased in postmenopausal women and this, despite
low levels of estrogens found in the circulation. Postme-
nopausally, breast cancer risk also increases with obesity
[1]. After menopause, when the ovaries no longer
produce measurable amounts of estrogens, an increase
in locally produced estrogens within the tumor and sur-
rounding adipose tissue is believed to drive tumor
growth via the action of markedly high levels of the aro-
matase enzyme (reviewed in [2]). The enhanced local
expression of aromatase within the breast is mediated
via promoter switching from distal promoter I.4 to the
alternative proximal promoter II (PII) on the CYP19A1
gene in response to inflammatory mediators derived
from the tumor, such as prostaglandin E2 (PGE2) [3,4].
A recent study demonstrated that PGE2 is also increased
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in breast tissues from overweight and obese women and
is associated with higher aromatase transcript expression
[5]. One of the transcription factors shown to be
involved in this process is cAMP response element
(CRE) binding protein-1 (CREB1) which binds to the
proximal and distal CREs on PII, and stimulates the
expression of aromatase [6]. CREB1-coactivators, includ-
ing CRTC2 [7], CBP [8] and p300 [9], are also known to
regulate PII-driven aromatase expression.
Many breast cancers are associated with heterogeneously
distributed hypoxic tissue areas within the tumor mass [10]
and hypoxia inducible factor-1a (HIF-1a) is found to be a
key mediator of hypoxia-mediated tumor responses
(reviewed in [11]). Previous studies have demonstrated that
HIF-1a is a novel prognostic marker in determining the
aggressive phenotype of breast cancer [12,13] and is emer-
ging as a potential target for cancer treatment [14,15]. HIF-
1 consists of two subunits, namely HIF1-a and HIF-1b,
which belong to the basic-helix-loop-helix (bHLH) protein
family containing a per-aryl hydrocarbon receptor nuclear
translocator-sim (PAS) domain [16]. HIF-1b is continu-
ously expressed and HIF-1a is continuously synthesized
and degraded under normoxic conditions mainly through
ubiquitin-proteasome dependent pathways after hydroxyla-
tion by prolyl-hydroxylases (PHDs) [17,18]. Under hypoxic
conditions, HIF-1 is stabilized and binds to core hypoxia
response elements (HREs) containing the 5’-RCGTG-3’
sequence [19] with other transcription factors, such as
CBP/p300 via its CH1 domain [20], which results in the
transcriptional activation of hypoxia-regulated genes
including vascular endothelial growth factor (VEGF),
known to promote angiogenesis (reviewed in [21]). In PC-3
ML human prostate cancer cells [22] and in HCT116
human colon carcinoma cells [23], it was demonstrated
that PGE2 and hypoxia act both independently and syner-
gistically to increase HIF-1a protein levels, and further
demonstrated the time-dependent nuclear accumulation of
HIF-1a in response to PGE2.
We have identified a putative HRE which overlaps
with the proximal CRE of aromatase PII. These findings
led us to hypothesize that HIF-1a may have a role in
regulating aromatase expression in response to the




The CYP19A1 PII-516 luciferase reporter plasmid, which
contains 502 bp (-516 to -14) of the proximal promoter
PII was generated as previously described [24]. The HA-
HIF-1a-pcDNA vector (Addgene, Cambridge, MA, USA),
plasmid 18949) was generated as previously described
[25]. The pCMV.CREB1 plasmid was purchased from Pro-
mega Australia (Alexandria, NSW, Australia).
Human tissue, cell culture
Primary human breast ASCs were isolated by collagenase
digestion of subcutaneous adipose tissue from women
undergoing reduction mammoplasty and cultured in Way-
mouth’s medium (Life Technologies Australia Pty Ltd,
Mulgrave, VIC, Australia), as previously described [26].
The studies have been approved by Southern Health
Human Research Ethics Committee B (#B00109). MCF-7
cells (human breast adenocarcinoma cell line) were cul-
tured in Dulbecco’s modified Eagle’s medium (Invitrogen,
USA). Before treatments, cells were serum-starved for 24
hours in medium containing 0.1% bovine serum albumin.
Treatments included prostaglandin E2 (PGE2, 1 μM) and
dimethyloxalglycine (DMOG, 100 μM; prolyl-4-hydroxy-
lase inhibitor which stabilizes HIF-1a) purchased from
Sigma-Aldrich Pty Ltd (Sydney, NSW, Australia). Sections
of formalin-fixed and paraffin-embedded breast tissues
from 10 Japanese breast cancer patients (IDC, invasive
ductal carcinoma and DCIS, ductal carcinoma in situ),
with differing hormone receptor status and grade (Addi-
tional file 1, Table S1), and 10 cancer-free women were
used for double immunohistochemistry studies. Japanese
female patients with IDC and DCIS were obtained from
St. Luke’s International Hospital (Tokyo, Japan). The
informed consent being obtained from these patients
before surgery and the research protocols were approved
by the ethics committee at St Luke’s International Hospital
(2010-509). All the clinical data were retrieved from the
relevant patient’s file and the histological grade was inde-
pendently evaluated.
Nuclear extraction and Western blot analysis
Primary breast ASCs were cultured on 10 cm plates and
treated as described above. Nuclear extracts were obtained
as described in the Abcam technical website with minor
modifications, including addition of cobalt chloride
(1 mM) and protease inhibitor cocktail tablet-complete
mini from Roche Products Pty Ltd (Dee Why, NSW,
Australia). BCA protein assay (Thermo Fisher Scientific
Australia Pty Ltd, Scoresby, VIC, Australia) was performed
to quantify protein amount according to the manufac-
turer’s instructions. A total of 10 μg of nuclear protein
diluted in loading buffer containing b-mercaptoethanol
was run on 10% denaturing polyacrylamide gel and trans-
ferred to nitrocellulose membrane. HIF-1a and histone
H3 protein levels were detected using HIF-1a (sc-10790;
1/200 dilution, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), histone H3 (ab1791; 1/10,000 dilution; Sapphire
Bioscience Pty Ltd, Waterloo, NSW, Australia) and Alexa
Fluor 700 goat anti-rabbit secondary (1/10,000 dilution,
Invitrogen, USA) antibodies using the Odyssey infrared
imaging system (LI-COR Biosciences, Lincoln, NE, USA).
The intensity of the bands detected from Western blotting
was quantified using densitometric analysis.
Samarajeewa et al. Breast Cancer Research 2013, 15:R30
http://breast-cancer-research.com/content/15/2/R30
Page 2 of 12
Reverse transcription and quantitative PCR (QPCR)
Total RNA was extracted using the RNeasy Mini Kit
(QIAGEN Pty Ltd, Chadstone, VIC, Australia) and 0.3 to
1 μg of RNA was reverse transcribed using the AMV RT
Kit using oligo-dT primer (Promega Australia, Alexandria,
NSW, Australia) as directed by the manufacturer. DNA
was digested using the DNA-free DNase Treatment and
Removal Kit ((Life Technologies Australia Pty Ltd, Mul-
grave, VIC, Australia). QPCR was performed on the Light-
Cycler using LightCycler FastStart DNA Master SYBR
Green l kit (Roche Products Pty Ltd, Dee Why, NSW,
Australia). Quantification of human HIF-1a, human aro-
matase and b-actin or 18 s (housekeeping genes) tran-
scripts was carried out using primers hHIF-1a F: 5’-
GTACCCTAACTAGCCGAGGAAGAA-3’, hHIF-1a R:
5’-GTGAATGTGGCCTGTGCAGT-3’, hArom F: 5’-TT
GGAAATGCTGAACCCGAT-3’, hArom R: 5’-CAGGA
ATCTGCCGTGGGGAT-3’, b-actin F: 5’-TGCGTGACA
TTAAGGAGAAG-3’, b-actin R: 5’- GCTCGTAGCT
CTTCTCCA -3’, 18S-F: 5’-CGGCTACCACATCCAAG-
GAA-3’ and 18S-R: 5’GCTGGAATTACCGCGGCT-3’.
Cycling conditions were one cycle at 95°C for 10 minutes
followed by 40 cycles of 95°C for 10 sec, 59°C for 6 sec and
72°C for 4 sec for HIF-1a, 40 cycles of 95°C for 10 sec,
60°C for 5 sec and 72°C for 10 sec for aromatase and
30 cycles of 95°C for 10 sec, 59°C for 5 sec and 72°C for
10 sec for b-actin or 18 s. All the samples were quantified
using standards of known concentrations and corrected
for abundance with the housekeeping gene b-actin or 18 s.
Immunofluorescence and confocal imaging
HIF-1a protein was visualized in primary breast ASCs
using immunofluorescence and confocal microscopy.
ASCs were plated onto coverslips and cultured until
they reached approximately 70% confluency. Cells were
serum-starved overnight and treated for 24 hrs. Immu-
nofluorescence was performed as previously described
[27], using HIF-1a antibody (sc-10790; 1/2,000 dilution,
Santa Cruz Biotechnology, USA) and lamin B1+B2 anti-
body (1/1,000 dilution, Abcam, USA) for nuclear stain
and visualized using alexa fluor-546 (red) and -488
(green) from Invitrogen (USA), respectively, using con-
focal microscopy (Olympus Australia Pty Ltd, Mt
Waverley, VIC, Australia).
High content screening
Primary breast ASCs cells were plated in 96-well plates at a
density of 6,000 cells per well. One day after plating, the
cells were serum-starved for 24 hours and treated with
PGE2 for 6 hours. Fixation was carried out in ice-cold
methanol for 40 minutes at -20°C, followed by 2 × PBS
washes. Cells were blocked in 0.5% BSA/PBS for 30 min-
utes and incubated with HIF-1a antibody (sc-10790; 1/
2,000 dilution in 0.5% BSA/PBS, Santa Cruz Biotechnology,
USA) overnight at 4°C with gentle rocking. After 2 × PBS
washes, alexa fluor 488 goat anti-rabbit secondary antibody
(1/1,000 dilution, Invitrogen, USA) and Hoechst nuclear
counterstain (1/5,000 dilution) in 0.5% BSA/PBS were
applied for 90 minutes. In order to quantitate nuclear
fluorescence, images were captured on an ArrayScan VTI
instrument (Thermo Fisher Scientific Australia Pty Ltd,
Scoresby, VIC, Australia) and analyzed using Cellomics
software (Thermo Fisher Scientific Australia Pty Ltd, Scor-
esby, VIC, Australia) and the Compartmental Analysis
Bioapplication (Thermo Fisher Scientific Australia Pty Ltd).
The analysis algorithm used Hoechst fluorescence to define
a mask used to measure nuclear fluorescence. Threshold
for nuclear staining was determined by assessing nuclear
intensity in negative control samples and set to two stan-
dard deviations. Cells with nuclear HIF-1a pixel intensity ≥
230 were considered HIF-1a positive.
Chromatin immunoprecipitation (ChIP)
Primary breast ASCs treated with PGE2 or DMOG for 45
minutes were used for ChIP to examine endogenous bind-
ing of HIF-1a to aromatase PII using the ChIP-IT express
kit (Active Motif, Carlsbad, CA, USA) as directed by the
manufacturer with minor modifications [7]. Briefly, cells
were fixed using 1% formaldehyde to cross-link and pre-
serve endogenous protein-DNA interactions. The DNA
was then sheared into small fragments using sonication at
20% amplitude, seven times for 30 sec pulses. Specific pro-
tein-DNA complexes were immune-precipitated using
HIF-1a antibody (Santa Cruz Biotechnology, USA), IgG
or water as controls. QPCR was then performed using
primers flanking the CREs of CYP19A1 PII (PII-ChIP-F:
5’-TTTCCACACTACCGTTGGCCG-3’ and PII-ChIP-R:
5’-GGCAATCTTCTTCCCTTGAAGC-3’), and normal-
ized to input DNA [7].
Reporter gene assays
MCF-7 cells were transfected with wild type or proximal
CRE mutated CYP19A1 PII-516 luciferase constructs, with/
without human HIF-1a-pcDNA (Addgene, Cambridge,
MA, USA) and/or human CREB1-pcDNA or with HIF-1a
siRNA (sc-35561, Santa Cruz Biotechnology, USA) or con-
trol siRNA-A (sc-37007, Santa Cruz Biotechnology, USA),
using the cell line nucleofector kit V, program E-014
(Lonza, Tullamarine, VIC, Australia), according to the
manufacturer’s instructions. b-galactosidase was co-trans-
fected and used as a transfection control. After transfec-
tion, cells were serum-starved and treated with FSK/PMA
and/or DMOG for 24 hours. Luciferase reporter assays
were carried out using the Dual-Glo Luciferase Assay Sys-
tem (Promega, USA) according to the manufacturer’s pro-
tocol and data were normalized to b-galactosidase activity.
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Aromatase activity assay (tritiated water-release assay)
Primary breast ASCs and MCF-7 cells were plated in
six-well plates. MCF-7 cells were transfected with 2 μg
of human HIF-1a-pcDNA (Addgene, USA) or 3 μl of
HIF-1a siRNA (sc-35561, Santa Cruz Biotechnology,
USA) or control siRNA-A (sc-37007, Santa Cruz Bio-
technology, USA) using lipofectamine transfection
reagent (Invitrogen, USA), as directed by the manufac-
turer. ASCs and MCF-7 cells were serum-starved for
24 hours and treated with specified reagents. Aromatase
activity in these cells was measured using the tritiated
water-release assay using androst-4-ene-3, 17-dione
(NET926001MC, PerkinElmer, Glen Waverley, VIC,
Austalia) as a substrate, as previously described [28].
Specific activity was normalized to total protein amount.
Double immunohistochemistry (IHC)
Formalin-fixed paraffin-embedded tissue sections from
breast cancer and cancer-free patients were de-waxed in
xylene and were rehydrated through descending concen-
trations of ethanol solutions to distilled H2O. Tissue sec-
tions were incubated in 10% horse serum in CAS-block
(Invitrogen, USA) for 30 minutes. Previously characterized
aromatase mouse monoclonal primary antibody 677 (1/
250 dilution from 2.6 mg/ml stock in 0.5% BSA/PBS, [29])
was added to the slides and incubated overnight at 4°C.
After washing in PBS, biotinylated universal secondary
antibody (1/200 dilution, Vectastain Universal ABC-AP
kit, Abacus ALS, East Brisbane, QLD, Australia) was
applied for 30 minutes and then incubated with Vectastain
ABC-AP reagent for 30 minutes. Alkaline phosphatase
substrate (Vector blue alkaline phosphate substrate kit,
Vector Laboratories, USA) was added until the desired
cytoplasmic blue stain intensity developed and the reac-
tion stopped with distilled H2O.
Slides were then subjected to antigen retrieval in an auto-
clave, at 121°C for 5 minutes in Tris EDTA pH 9 (10 mM
Tris base, 1 mM EDTA). After cooling for 30 minutes, sec-
tions were washed in PBS and incubated in 10% horse
serum in CAS-block (Invitrogen, USA) for 30 minutes.
The HIF-1a primary antibody (sc-10790; 1/250 dilution in
0.5% BSA/PBS, Santa Cruz Biotechnology, USA) was
added to the slides and incubated overnight at 4°C. After
washing in PBS, endogenous peroxidase activity was
blocked with 0.3% hydrogen peroxide for 30 minutes. Anti-
rabbit IgG secondary antibody (1/1,000 dilution, Vectastain
ABC-AP kit-rabbit IgG, Vector laboratories, USA) was
applied for 30 minutes and then incubated with Vectastain
ABC-AP reagent for 30 minutes. Slides were then stained
with 3,3’-diaminobenzidine tetrahydrochloride (DAB,
Sigma-Aldrich, USA) until desired nuclear brown stain
intensity developed and the reaction was stopped with dis-
tilled H2O. Finally, the sections were mounted with fluor-
save reagent (Merck Pty Ltd, Kilsyth, VIC, Australia).
Double immunohistochemically stained slides for HIF-
1a and aromatase were evaluated independently by two
observers (NUS and MS or NUS and KAB). The ASCs
were examined using systematic random sampling on a
stereology microscope (Olympus Australia Pty Ltd, Mt
Waverley, VIC, Australia) with the aid of CAST-Grid
version 1.60 (Olympus Australia Pty Ltd, Mt Waverley,
VIC, Australia) and categorized into four groups includ-
ing HIF-1a positive and aromatase positive, HIF-1a
positive and aromatase negative, HIF-1a negative and
aromatase positive, and HIF-1a negative and aromatase
negative (Additional file 2, Figure S1).
Statistical analysis
All data were expressed as mean ± standard error (SE).
Two-tailed Student’s t test was performed for experi-
ments comparing two groups. For experiments with mul-
tiple comparisons, statistical analysis was done using
one-way ANOVA followed by Bonferroni’s multiple com-
parison test. Statistical significance was defined as *, P <
0.05; **, P ≤ 0.005; ***, P ≤ 0.0005, ****, P ≤ 0.0001. Data
analysis was performed using GraphPad Prism version
5.00 (GraphPad Software, San Diego, CA, USA).
Results
PGE2 increases HIF-1a expression and nuclear localization
in primary human breast ASCs
The effect of PGE2 on HIF-1a transcript and protein
expression was examined in primary breast ASCs. HIF-1a
mRNA was significantly increased with PGE2 treatment
(Figure 1A). Moreover, Western blotting demonstrated
that PGE2 also caused a significant increase in HIF-1a pro-
tein abundance in the nucleus (Figure 1B). The subcellular
localization of endogenously expressed HIF-1a was exam-
ined using immunofluorescence and confocal microscopy
after treating with PGE2 and/or DMOG. Results demon-
strated that punctate staining for HIF-1a appears in the
nucleus after PGE2 treatment (Figure 1C, top right) com-
pared to cytoplasmic localization under basal conditions
(Figure 1C, top left). Furthermore, DMOG (Figure 1C, bot-
tom left) and DMOG with PGE2 (Figure 1C, bottom right)
resulted in more intense staining for HIF-1a in the
nucleus. Results from high content screening also demon-
strated that the percentage cells positive for HIF-1a in the
nucleus (Figure 1D) was significantly increased in response
to PGE2 treatment.
HIF-1a binds to aromatase promoter PII and increases
aromatase expression and activity in primary breast ASCs
The endogenous binding of HIF-1a to aromatase PII was
evaluated by ChIP. Treatment with either PGE2 or DMOG
resulted in a significant increase in binding of HIF-1a to
aromatase PII compared to vehicle control (Figure 2A).
Consistent with these findings, treatment of primary
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human breast ASCs with PGE2 or DMOG also caused a
significant increase in aromatase transcript expression (Fig-
ure 2B) and aromatase activity (Figure 2C). Overexpression
of HIF-1a in MCF-7 cells treated with PGE2 also resulted
in increased aromatase activity (Figure 2D).
HIF-1a acts cooperatively with CREB1 to increase PII
activity breast ASCs
PROMO 3.0 online putative transcription factor binding
site predictor [30] was used to identify a putative bind-
ing site of HIF-1a on aromatase PII [31,32]. Results
Figure 1 Effect of PGE2 on HIF-1a expression and nuclear localization in primary human breast ASCs. PGE2 caused a significant increase in HIF-
1a transcript (A) and nuclear protein expression (B). Confocal microscopy demonstrated that HIF-1a (green) is mainly perinuclear in breast ASCs under
basal conditions (C, top left) and that PGE2 stimulates the translocation of HIF-1a to the nucleus (C, top right). Treatment with DMOG (C, bottom left)
and DMOG with PGE2 (C, bottom right) caused a much higher HIF-1a staining in the nucleus. The merged lamin B1+B2 nuclear stain (red) and HIF-1a
are found as insets at the bottom right of each image. The percentage of cells positive for nuclear HIF-1a was also shown to be significantly increased
with PGE2 treatment (D). vc = vehicle control, n = 3, repeated twice. Confocal images are representative of the majority of cells examined.
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demonstrated that the predicted HRE overlaps with the
proximal CRE of aromatase PII (Figure 3A).
To determine the effect of HIF-1a on aromatase PII
activity, luciferase reporter assays were performed in
MCF-7 cells, transfected with HIF-1a and wild type or
proximal CRE mutated CYP19A1 PII-516 luciferase repor-
ter constructs and treated with DMOG. Cells transfected
with HIF-1a treated with DMOG and DMOG alone
showed a significant increase in promoter II activity,
and this HIF-1a/DMOG-mediated effect on promoter II
activity was completely abolished using a proximal CRE-
mutated PII reporter construct (Figure 3B). As the puta-
tive HRE overlaps with the proximal CRE on aromatase
PII, experiments were performed to determine whether
HIF-1a acted cooperatively or competitively with CREB1.
MCF-7 cells were transfected with HIF-1a and/or CREB1
together with the CYP19A1 PII-516 luciferase reporter
construct, and then treated with DMOG and/or PGE2. PII
activity was significantly increased in HIF-1a transfected
cells in the presence of PGE2 or DMOG, and treatment
with both PGE2 and DMOG led to a further significant
increase in PII activity (Figure 3C). Interestingly, cells
transfected with both HIF-1a and CREB1 showed a
further increase in PII activity (P ≤ 0.005) with both PGE2
and DMOG compared to cells transfected with either
HIF-1a or CREB1 alone (Figure 3C). Hence, HIF-1a and
CREB1 act cooperatively to increase PII activity.
HIF-1a is necessary for the PGE2-mediated induction of
aromatase PII
Reporter assays were also performed to examine the
requirement of HIF-1a for the PGE2-mediated increase
Figure 2 Role of HIF-1a in aromatase regulation. (A) ChIP demonstrated that PGE2 and DMOG significantly stimulate the endogenous
binding of HIF-1a to aromatase PII. Treatment of ASCs with PGE2 or DMOG caused a significant increase in aromatase transcript expression (B)
and activity (C). (D) HIF-1a overexpression in MCF-7 cells significantly increased aromatase activity in the presence of PGE2. vc = vehicle control,
n = 3, repeated twice.
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in PII activity. MCF-7 cells transfected with HIF-1a
siRNA showed a significant reduction in aromatase PII
activity (Figure 3D) and aromatase transcript (Figure
3F), and the PGE2-mediated effect on PII via HIF-1a
was suppressed (Figure 3D).
HIF-1a is increased in ASCs from tumor-bearing breast
tissues compared to cancer free breast tissue
Double immunohistochemistry was performed on for-
malin-fixed, paraffin-embedded (FFPE) tissues from
breast cancer patients and cancer-free women. Results
Figure 3 HIF-1a is necessary and acts cooperatively with CREB1 to induce PII activity in response to PGE2. (A) A putative HRE (italic) was
found to overlap with the proximal CRE (boxed) of aromatase PII. (B) Reporter assays demonstrated that mutation of the proximal CRE of
aromatase PII inhibited the HIF-1a/DMOG-mediated effect on PII activity. (C) PII activity was significantly increased in HIF-1a transfected cells,
treated with DMOG and PGE2, and co-transfection with CREB1 resulted in a further increase in PII activity compared to cells transfected with
either HIF-1a or CREB1 alone. Knockdown of HIF-1a (E) using siRNA significantly reduced PII activity (D) and aromatase transcript expression
(F) and suppressed the PGE2-mediated effect on PII activity (D). b-gal, b-galactosidase activity; RLU, relative luciferase units. N = 3, all experiments
repeated twice.
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demonstrated that there is a significant increase in the
percentage of HIF-1a positive ASCs in breast cancer
patients compared to cancer-free women (Figure 4A).
Interestingly, ASCs, which were HIF-1a and aromatase
double-positive and which were single-positive for HIF-1a
or aromatase, were significantly increased in tumor
patients compared to cancer-free women (Figure 4B).
Furthermore, double negative ASCs were significantly
decreased in tumor cases compared to normal (Figure 4B),
and the percentage of cells either double-positive or dou-
ble-negative was significantly higher than single-positive
cells (analysis not shown), suggesting a positive association
between HIF-1a and aromatase expression.
Discussion
In this study, novel evidence is provided for the regula-
tion of HIF-1a and its role in regulating aromatase
expression in adipose stromal cells in the context of
obesity and breast cancer. Namely, that HIF-1a expres-
sion and nuclear localization are increased in response
to PGE2 and stimulate the promoter II-driven expres-
sion of aromatase in breast ASCs via binding to the
proximal CRE (Figure 5).
HIF-1a has been shown to be overexpressed in many
different types of tumors including those of the ovary,
prostate and breast [33]. However, the expression and
regulation of HIF-1a in cancer-associated adipose stro-
mal cells is less well characterized. Here, we demonstrate
that HIF-1a transcript, protein expression and protein
nuclear localization are increased in breast ASCs in
response to the tumor-derived factor PGE2. Consistent
with these observations, we also demonstrate that in clin-
ical samples, the number of HIF-1a positive ASCs is
increased in breast cancer patient samples compared to
cancer-free breast tissue. Despite the limited number of
patient samples examined and these being from women
with differing tumor grade, the dramatic increase
observed was highly conserved among all patients. How-
ever, the majority of cases were postmenopausal women
with hormone receptor positive tumors. Nevertheless, it
has been reported that the majority of breast tumors
overexpress COX-2 and secrete high levels of PGE2
[34,35]. Our results are consistent with observations
demonstrating that PGE2 causes the stabilization of HIF-
1a independent of hypoxia in PC-3 ML human prostate
cancer cells [22], HCT116 human colon carcinoma cells
[23] and AGS gastric carcinoma cells [36]. However, to
our knowledge, this is the first report to demonstrate an
increase in HIF-1a transcript levels in response to PGE2
in ASCs.
The PGE2-induced up-regulation of HIF-1a has been
shown to be mediated through EP2 and EP4 receptor
activation in PC-3 ML cells [22] and the EP1 receptor
alone in HCT116 cells [23]. In human embryonic kidney
cells expressing the human EP1 receptor, PGE2 has been
shown to up-regulate HIF-1a protein expression in a
time-dependent manner under normoxic conditions
[37]. Interestingly, the expression of EP receptors has
been demonstrated in breast ASCs and the regulation of
aromatase by PGE2 in these cells has been shown to be
dependent on activation the EP1 and EP2 receptors
[4,38]. These data suggest that aromatase up-regulation
via EP receptor activation may involve the induction of
HIF-1a. Indeed, HIF-1a increases the activity of aroma-
tase PII, and the increased nuclear localization and
punctuate appearance of HIF-1a in response to PGE2 is
also associated with the increased binding of HIF-1a to
aromatase PII via the proximal CRE. The regulation of
aromatase by HIF-1a has also recently been examined
in the context of placental aromatase regulation. In that
case, aromatase expression is mediated by distal placen-
tal-specific promoter I.1 and is dependent on binding of
estrogen-related receptor g (ERRg) to the promoter [39].
Hypoxia has been shown to cause the HIF-1a-depen-
dent down-regulation of ERRg [39]. Contrary to our
findings, the HIF-1a-mediated effects on PI.1 are inhibi-
tory and appear to be indirect.
Promoter analysis revealed that a putative core HRE
sequence is present on the antisense strand of aromatase
PII and overlaps with the proximal CRE, suggesting that
HIF-1a may interact with CREB1 in ASCs. Previous stu-
dies have demonstrated that CREB1 binds to the HRE in
the plasminogen activator inhibitor-1 (PAI-1) promoter
[40] and HIF-1a can also interact with ATF2/CBP/p300
[41-43]. There is a significant elevation in CREB1 tran-
script expression in breast tumor tissues compared to
non-neoplastic breast tissues and this is positively asso-
ciated with poor prognosis, metastatic disease and nodal
involvement [44,45]. Interestingly, the present study
demonstrates that HIF-1a alone can stimulate aromatase
promoter PII and that it also acts cooperatively with
CREB1 to increase aromatase PII activity.
The local biosynthesis of estrogens from breast ASCs is
considered a key mediator of tumor cell growth in postme-
nopausal breast cancer, and increased PII activity accounts
for the majority of transcripts detected [3]. We have
observed that the majority of ASCs in the tumor-bearing
tissue are either double-positive or double-negative for
HIF-1a and aromatase expression, suggesting an associa-
tion between the two proteins. These findings support our
in vitro data demonstrating that HIF-1a directly stimulates
aromatase expression.
Collectively, the results obtained in this study show for
the first time that HIF-1a activates PII-driven aromatase
expression in breast ASCs in response to PGE2, indepen-
dent of oxygen availability. Hence, this specific associa-
tion is likely to be an important mechanism for the
regulation of estrogen biosynthesis in obesity-related,
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postmenopausal breast cancer. Third-generation aroma-
tase inhibitors (AIs) are currently the most effective treat-
ment and have been shown to be superior to tamoxifen
for hormone receptor positive, postmenopausal breast
cancer as aromatase catalyses the conversion of circulat-
ing androgenic precursors to estrogens [46-48]. However,
many women cease use of AIs due to increasingly severe
side-effects associated with their use [49-51]. Currently,
small molecule inhibitors of HIF-1a are being tested in
the clinical setting (reviewed in [52]). We believe that
better understanding of the regulation of aromatase PII
will allow us to target aromatase expression specifically
within the breast, leaving sites such as the bone, brain
and heart, where estrogens have beneficial effects,
unaffected.
Conclusions
This study demonstrates that HIF-1a, a master regulator
of oxygen homeostasis, stimulates PII-driven aromatase
expression in human breast ASCs with other transcription
Figure 4 HIF-1a and aromatase expression in ASCs from tumor-bearing breast tissue compared to cancer-free using
immunohistochemistry. (A) Percentage of HIF-1a positive ASCs from tumor-bearing breast tissue was significantly increased compared to
tissue from cancer-free women. (B) Double-positive and single-positive ASCs for HIF-1a and aromatase were shown to be significantly increased
in tumor-bearing compared to cancer-free tissues. Double negative ASCs for HIF-1a and aromatase were significantly reduced in tumor-bearing
compared to cancer-free tissues. n = 10 for tumor-bearing breast tissue; n = 10/cancer-free breast tissue.
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factors, including CREB1, in response to tumor-derived
and obesity-associated inflammatory mediator PGE2. Our
findings of HIF-1a in tumor-associated breast stroma
implicate its potential as a therapeutic target in obesity-
related, postmenopausal breast cancer.
Additional material
Additional file 1: Table S1: Clinicopathological data of breast cancer
patients. Formalin-fixed and paraffin-embedded breast tissues from 10
Japanese breast cancer patients (IDC and DCIS), with differing hormone
receptor status and grade used in Figure 4 are listed.
Additional file 2: Figure S1: Classification of ASCs for double
immunohistochemistry. (A, B; arrows) HIF-1a and aromatase double
positive cells. (C, D; arrows) HIF-1a positive and aromatase negative cells.
(E, F; filled arrows) HIF-1a negative and aromatase positive cells. (E,
empty arrow) HIF-1a positive and aromatase positive cell. (F, empty
arrow) HIF-1a and aromatase double negative cell. Blue color in the
cytoplasm as a result of Vector blue colorimetric reaction represents
aromatase immunoreactivity while brown color in the nuclei as a result
of DAB colorimetric reaction represents HIF-1a immunoreactivity.
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